Fractyl Health Inc (GUTS) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in...

Form 8-K - Current report

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and...

Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024

Single Revita procedure led to sustained, clinically meaningful weight loss in majority of patients with Type 2...

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

BURLINGTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

BURLINGTON, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference

BURLINGTON, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Fractyl Health to Participate in Upcoming September Investor Conferences

BURLINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Form 8-K - Current report

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Updated clinical results from German Real-World Registry demonstrate potential for Revita® to meaningfully...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure

Median weight decreased from 111 kilograms (245 pounds) to 97 kilograms (214 pounds), representing nearly 13...

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

BURLINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a...

Form 8-K - Current report